910823-59-5

Basic information

• Product Name: (2R,4R)-2-[2-fluoro-4-(2-oxo-pyridin-1-yl)-phenylcarbamoyl]-4-methoxy-pyrrolidine-1-carboxylic acid tert-butyl ester
• Synonyms: (2R,4R)-2-[2-fluoro-4-(2-oxo-pyridin-1-yl)-phenylcarbamoyl]-4-methoxy-pyrrolidine-1-carboxylic acid tert-butyl ester
• CAS NO: 910823-59-5
• Molecular Weight: 431.464
• Mol File: 910823-59-5.mol

Chemical Properties

• CAS DataBase Reference: (2R,4R)-2-[2-fluoro-4-(2-oxo-pyridin-1-yl)-phenylcarbamoyl]-4-methoxy-pyrrolidine-1-carboxylic acid tert-butyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: (2R,4R)-2-[2-fluoro-4-(2-oxo-pyridin-1-yl)-phenylcarbamoyl]-4-methoxy-pyrrolidine-1-carboxylic acid tert-butyl ester(910823-59-5)
• EPA Substance Registry System: (2R,4R)-2-[2-fluoro-4-(2-oxo-pyridin-1-yl)-phenylcarbamoyl]-4-methoxy-pyrrolidine-1-carboxylic acid tert-butyl ester(910823-59-5)

Safety Data

• Hazardous Substances Data: 910823-59-5(Hazardous Substances Data)

Upstream product

• 135042-12-5 (4R)-1-(tert-butoxycarbonyl)-4-hydroxy-D-proline 
• 29632-74-4 2-fluro-4-iodoaniline 
• 675-20-7 piperidin-2-one 
• 200184-87-8 (2R,4R)-1-(tert-butoxycarbonyl)-4-methoxypyrrolidine-2-carboxylic acid 
• 536747-52-1 1-(4-amino-3-fluoro-phenyl)-pyridin-2-one 

Downstream Products

• 910823-60-8 (2R,4R)-4-methoxy-pyrrolidine-2-carboxylic acid [2-fluoro-4-(2-oxo-pyridin-1-yl)-phenyl]-amide 

Relevant articles and documents

CRYSTALLINE FORMS OF A KNOWN PYRROLIDINE FACTOR XA INHIBITOR

Disclosed are crystalline forms A, B and C of 1 ,2-Pyrrolidinedicarboxamide, N1 -(4- chlorophenyl)-N2-[2-fluoro-4-(2-oxo-1 (2H)-pyridinyl)phenyê]-4-methoxy-, (2R,4R)- (9Cl). These crystalline forms are characterized by their powder X-ray diffraction, solid-state NMR, as well as methods for the preparation and pharmaceutical compositions of the same which are useful for the treatment of acute, subacute, or chronic thrombotic disorders including treatment of venous thrombosis, arterial thrombosis, pulmonary embolism, myocardial infarction, cerebral infarction, restenosis, atherosclerosis, angina, primary and secondary deep vein thrombosis, thromboembolism associated with cardiovascular disease, including, but not limited to, acute coronary syndrome, atrial fibrillation, cardiac valve replacement and deep vein thrombosis. The crystalline forms of the present invention are also useful for the treatment of cancer, sepsis and diabetes.